Angiotensin II receptor antagonists (AT-1) represent a new group of orally active antihypertensive agents. Activation on AT-1 receptor leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone with production of thirst, and promote growth of vascular and cardiac muscle; these effects are blocked by AT-1 antagonist agents. The first chemically useful, orally active AT-1 receptor antagonist was losartan, followed by other agents currently in clinical use, such as: valsartan, eprosartan, irbesartan, telmisartan, candesartan, and many others under investigation. AT-1 receptor antagonists are effective in reducing high blood pressure in hypertensive patients. Monotherapy in mild to moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of
Introduction
Saralasin was the first receptor antagonist of angiotensin II available for clinical use more than 20 years ago. 1, 2 Saralasin is a peptide analogue of angiotensin II with partial agonist effect, and can only be used intravenously; it has a very short duration of action. When salarasin is used there is an initial increase in arterial blood pressure, due to its partial agonist effect, but prevents the increment of blood pressure when angiotensin II is administrated.
Furukawa et al 3 was the first to synthesise an imidazole derivative that was found to be a selective angiotensin II receptor competitive antagonist, and after chemical modifications, orally active agent. 4 Losantan was the first orally active, and long-acting receptor antagonist developed and in use in the treatment of hypertension, 5, 6 followed by valsartan, irbesartan, eprosartan, candesartan, telmisartan and others. 7 Blockade of renin-angiotensin system is efficacious and a safe way to reduce blood pressure as a treatment of patients with hypertension and heart failure, mainly by the inhibition of angiotensinconverting enzyme (ACE). The main side effects observed with ACE inhibitors is cough and angioedema, which is seen in 5 to 10% of patients treated. 8 the advantage in having a very low incidence of such side effects. However the place of this class of antihypertensive action remains to be defined.
Angiotensin II receptors
Angiotensin II exerts its effects by stimulating some specific receptors on the membrane of several organs. Radioligand studies have characterised several angiotensin II receptors, mainly type I and type II (AT-1 and AT-2 receptor). Activation of AT-1 receptor leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and production of thirst; also promoting growth effects in vascular and cardiac muscle, 9 all these effects are blocked by AT-1 antagonists. Activation of AT-2 receptors tends to have opposite reaction basically cardio-protective effects by inhibitory effects on growth mechanisms at vascular and cardiac level.
AT-2 receptors are expressed during the intrauterine life but not during adult life; however in pathological situations, such as myocardial infarction, left ventricular hypertrophy and in vascular neointimal proliferation, the AT-2 receptors are re-expressed; in those conditions AT-2 receptor stimulation may produce some protection in the heart and vessels. When AT-1 receptor antagonists block AT-1 receptors, actions of AT-1 receptors are inhibited but angiotensin II produce stimulatory effect on AT-2 receptors. 10 Actions mediated by AT-1 and AT-2 receptors are summarised in Table 1 . Other angiotensin II receptors have been described such as AT-3 ant AT-4;
11 in rats and mice, AT-1 receptor is also composed of two subtypes: AT-1A and AT-1B; 12 these receptors have to be characterised pharmacologically and determinate its relevance in man during physiological and pathophysiological conditions.
AT-1 antagonists
The first chemically useful, orally active AT-1 receptor antagonist was losartan, followed by other agents currently in clinical use or under investigation. 5, 6 Table 2 summarises the AT-1 receptor antagonist either in clinical use or under development:
The AT-1 receptor antagonists reduce blood pressure by decreasing systemic vascular resistance; heart rate and cardiac output are not modified. [13] [14] [15] Reduction in systemic vascular resistance are due to inhibition of the direct vasoconstrictive effect of angiotensin II, reductions in the sympathetic nervous system activity, in the release of aldosterone and in the reabsortion of sodium, are mediated by angiotensin II. It has also been described as sensitising in baroreceptors, the stimulation of prostacyclin release, and at long-term reduction in the proliferative effect (antiproliferative effect). 7 In volunteers the administration of AT-1 receptor antagonists increase plasma renin activity and angiotensin II levels either in acute administration or multiple dose administration; 16, 17 but the pressure effect of angiotensin II is blocked. Whereas ACE inhibitors reduce plasma level of angiotensin II and increase bradykinin levels.
The efficacy in reducing blood pressure with the use of AT-1 receptor antagonists is equivalent to other well established antihypertensive agents. When losartan (50 to 100 mg daily) is compared to felodipine (5 to 10 mg daily, losartan was less effective after 6 weeks of treatment but equally effective after 12 weeks of therapy). 18 The efficacy of losartan (50 to 100 mg once daily) has been compared to atenolol (50 to 100 mg once daily), and enalapril (20 mg once daily). The blood pressure lowering effect of losartan was comparable to enalapril and atenolol. On ambulatory blood pressure monitoring losartan showed antihypertensive effect over a period of 24 h without affecting the body's circadian rhythm. 19, 20 Several studies have compared the blood pressure lowering effects of AT-1 receptor antagonist against enalapril; candesartan cilexitil, 21 eprosartan 22 and irbesartan 23 lower systolic and diastolic blood pressure to the same extent to that of enalapril.
When diuretics were added to an AT-1 receptor antagonist, a better response is achieved. The addition of hydrochorothiazide to losartan produce a dose-related reduction in blood pressure after a treatment of 12 weeks. 19 In a double-blind study 189 patients were enrolled to compare valsartan + HCTZ (12.5 mg) and Enalapril + HCTZ (12.5 mg), which after 8 weeks of treatment controlled blood pressure in about 64% of the patients in both group of treatments. 24 Losartan has been shown to exert a uricosuric effect in normotensive and hypertensive subjects, which could be an advantage when losartan is combined with a thiazide diuretic.
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Effect on left ventricular hypertrophy ACE inhibitors are particularly effective in reducing and perhaps preventing left ventricular hypertrophy in hypertensive patients mediated by several mechanisms, such as the reduction of circulating angiotensin II and aldosterone and increment of bradykinin. 25, 26 Losartan and other AT-1 receptor antagonists reduce left ventricular hypertrophy in spontaneously hypertensive rats; 27 even at dosages that do not affect either blood pressure or the circulating renin-angiotensin system. 28 Thü rmann PA et al 29 in a double-blind randomised trial on 69 previously untreated hypertensive patients comparing valsartan (80 to 160 mg daily) to atenolol (50 to 100 mg daily) over 8 months, found that valsartan reduced left ventricular mass index to a higher extent than atenolol with similar reduction in systolic and diastolic blood pressure. Further documentation of the effects on left ventricular hypertrophy and long-term benefit and risk reduction will have to be evaluated in other trials. Adapted from Brunner.
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Pharmacokinetic
All AT-1 receptors antagonists studied to-date essentially seem to share the same pharmacodynamic characteristics, but these agents differ in their pharmacokinetic characteristics in relation to absorption, bioavailability, metabolism, elimination, duration of action and half-life. Table 3 summarises the pharmacokinetics of some AT-1 receptor antagonists in clinical use. Only two agents have active metabolites, losartan and candesartan cilexitil, which contribute to the duration of action of those agents. Drugs with higher bioavailability are irbesartan and telmisartan; these drugs also have the longest half-life. All AT-1 antagonists are highly protein-bound. 30 
Side effects
Goldberg et al 31 reported data on the safety and tolerability of losartan in 2900 hypertensive patients treated in double-blind clinical trials. Headache (14.1%), upper respiratory infection (6.5%), dizziness (14.1%), asthenia/fatigue (3.8%), and cough (3.1%) were the clinical side effects most often reported in patients treated with losartan; and the frequency reported during the placebo were 17.2%, 5.6%, 2.4%, 3.9% and 2.6% respectively. The incidence of cough is similar to diuretic or placebo in contrast with an ACE inhibitor (8.8%).
Dizziness, upper respiratory tract infection, back pain, sinusitis, diarrhoea and pharyngitis have been reported to be 1 to 2% higher than placebo with different agents. 32 Chan P et al 33 compared the incidence of cough with the ACE inhibitor lisinopril, and the diuretic metolazone, with losartan in elderly hypertensive patients with previous histories of ACE inhibitor induced cough, in a randomised, double-blind, parallel group comparison of each drug during 10 weeks in 84 patients. The incidence of cough with losartan (18%) was significantly lower than lisinopril (97%), and similar to that for metolazone (21%).
Eprosartan, in a trial including 243 patients with mild to moderate hypertension, controlled blood pressure in 42%, with a dosage of 600 mg daily the total number of adverse events was similar in the eprosartan and placebo groups. 34 AT-1 receptor antagonists do not modify glucose tolerance with either cholesterol or triglycerides levels.
Drugs that act directly on the renin-angiotensin
Journal of Human Hypertension system can cause foetal and neonatal morbidity and death when administered to pregnant women, any of the AT-1 receptor antagonists should not be used during pregnancy and should be discontinued as soon as possible when pregnancy is detected.
Conclusions
AT-1 receptor antagonists are a new class of drugs used to treat hypertensive patients. They are effective in reducing systolic and diastolic blood pressure in mild to moderate hypertension in about 40% of treated patients when they are used in monotherapy; but its efficacy increment to 60 to 70% when used in combination with low dose diuretic agent. Blood pressure is reduced with about equal efficacy compared to ACE-inhibitors, beta-blockers and calcium channel blockers when these drugs are used in monotherapy. AT-1 receptor antagonists could be used in combination with most other antihypertensive agents in more severe hypertension.
AT-1 receptor antagonists are an important option for the treatment of hypertension, especially in patients who have been using ACE inhibitors and who present with cough or angioedema. Tolerability has been reported to be excellent with the use of AT-1 receptor antagonists.
The place in the antihypertensive therapy in a special population and different clinical conditions, such as left ventricular hypertrophy, associated heart failure, diabetes, and renal disease, has to be determined in a further large prospective clinical trial.
